EJNMMI Radiopharmacy and Chemistry, published by SpringerNature, stands at the forefront of research in the critical fields of radiopharmacy and nuclear medicine. With an impressive impact factor and a dedicated Open Access policy since 2016, this journal invites the global scientific community to share advancements in the synthesis, development, and application of radiopharmaceuticals within the realm of analytical chemistry and pharmacology. As evidenced by its notable categorizations, including Q1 in Analytical Chemistry and Radiology, Nuclear Medicine and Imaging, along with high Scopus rankings, EJNMMI offers a prestigious platform for rigorous peer-reviewed research that informs and inspires progress in medical imaging and therapeutics. The journal's commitment to accessibility fosters collaboration and innovation, making it an essential resource for researchers, medical professionals, and students seeking to advance their understanding and application of radiopharmaceuticals.

NUCLEAR MEDICINE REVIEW is a distinguished journal in the field of radiology, nuclear medicine, and imaging, published by VIA MEDICA in Poland. Since its transition to an open access format in 1999, this journal has been dedicated to promoting the dissemination of knowledge and research findings across a global audience. With a focus on innovative approaches and advancements in nuclear medicine, it aims to serve as a key resource for researchers, professionals, and students who are working to further the understanding of nuclear imaging and its applications. In 2023, the journal was classified in the Q3 category within Radiology, Nuclear Medicine and Imaging, and Q4 in the broader category of Medicine (miscellaneous), highlighting its growing reputation in the academic community. As of the latest assessments, the journal has been ranked #235 out of 333 in its field according to Scopus metrics, reflecting its commitment to excellence and the relevance of its published works. The NUCLEAR MEDICINE REVIEW is a pivotal platform for those engaged in cutting-edge research, providing insights that drive the evolution of medical imaging and therapeutic techniques.

NUKLEARMEDIZIN-NUCLEAR MEDICINE is a prestigious journal published by Georg Thieme Verlag KG, focusing on pivotal advancements in the fields of Nuclear Medicine, Radiology, and Imaging. Established in 1959, this journal has served as a critical platform for disseminating innovative research, reviews, and clinical guidelines until its anticipated convergence in 2024. With an ISSN of 0029-5566 and an E-ISSN of 2567-6407, NUKLEARMEDIZIN is acknowledged in the academic community as a Q3 category journal within Medicine (miscellaneous) and Radiology, Nuclear Medicine, and Imaging as of 2023, highlighting its ongoing contribution to the interdisciplinary dialogue in healthcare. Although the journal does not currently offer open access, it remains accessible to professionals and students through various academic databases, ensuring that cutting-edge knowledge in this growing field is shared widely. Researchers interested in the latest methods and technologies in Nuclear Medicine will find NUKLEARMEDIZIN a valuable resource for enhancing their work and understanding the complexities of modern imaging modalities.

NUCLEAR MEDICINE COMMUNICATIONS is a prestigious academic journal published by Lippincott Williams & Wilkins, focusing on the multifaceted field of nuclear medicine and its applications in diagnostics and therapy. With a solid history spanning from 1980 to 2024, this journal provides a platform for peer-reviewed research articles, clinical studies, and innovative techniques that enrich the knowledge base within the fields of {{medicinal applications, patient care, and imaging technology}}. Currently classified in the Q3 quartile for both Medicine (Miscellaneous) and Radiology, Nuclear Medicine, and Imaging, the journal reflects its commitment to advancing healthcare practices. Although it does not offer open access options, its accessibility through reputable institutions promotes scholarly exchange among researchers, professionals, and students alike. The critical insights provided in NUCLEAR MEDICINE COMMUNICATIONS are essential for those dedicated to enhancing patient outcomes through cutting-edge nuclear medical technologies.

Medicine Nucleaire-Imagerie Fonctionnelle et Metabolique is a prominent journal published by Elsevier France-Editions Scientifiques Medicales Elsevier, dedicated to the specialized fields of nuclear medicine and functional imaging. With an ISSN of 0928-1258 and an E-ISSN of 1878-6820, this esteemed publication has been a crucial platform for the dissemination of research and developments in the discipline since its inception in 1993. Covering a wide array of topics within biophysics, radiological and ultrasound technology, and radiology, the journal currently holds a Q4 category ranking in these fields, reflecting its significance within the academic community. Although there are currently no open access options available for readers, the journal caters to a niche audience of researchers, professionals, and students who seek to enhance their understanding of metabolic imaging and its applications. The 2023 Scopus ranks indicate its position as an emerging source of knowledge in a competitive landscape, making it an important resource for the latest studies and innovations in nuclear medicine.

The American Journal of Nuclear Medicine and Molecular Imaging (ISSN: 2160-8407), published by E-CENTURY PUBLISHING CORP, is a distinguished platform for the dissemination of cutting-edge research in the fields of nuclear medicine and molecular imaging. With a commitment to advancing scientific inquiry and clinical applications, this journal serves as a vital resource for researchers, clinicians, and students dedicated to exploring innovative imaging modalities, radiopharmaceuticals, and their applications in diagnosing and treating various medical conditions. Although currently not available as an open-access journal, this publication plays a crucial role in fostering academic dialogue and collaboration within the medical community. Its diverse range of topics and expert contributions underscore its impact in bridging the gap between research findings and clinical practice, making it an essential read for anyone interested in the rapidly evolving landscape of nuclear medicine and imaging technologies.

Translational Cancer Research, published by AME Publishing Company in Hong Kong, is a pivotal journal aimed at fostering the advancement of oncology-related knowledge through the dissemination of high-quality research findings. With its ISSN 2218-676X and E-ISSN 2219-6803, this journal serves as a vital resource for researchers, professionals, and students in the fields of Cancer Research, Oncology, and Radiology, Nuclear Medicine, and Imaging. Established in 2012, the journal covers the latest breakthroughs and cross-disciplinary approaches that drive innovation in cancer treatment and diagnostics. Although currently classified in the Q4 Quartile for Cancer Research and Q3 for both Oncology and Radiology, Translational Cancer Research continuously works toward improving its academic influence and impact, evidenced by its ongoing research contributions. The journal emphasizes open access, making crucial research available to a global audience. We invite scholars and industry professionals to engage with the latest findings and discussions within these critical areas of medical science.

PET Clinics, published by Elsevier Inc, is a premier academic journal focusing on the advancements and applications of Positron Emission Tomography (PET) in various medical fields. With its ISSN 1556-8598 and E-ISSN 1559-7814, the journal has established a strong reputation in the scientific community, reflected in its impressive Q1 quartile rankings in Medicine (miscellaneous), Radiation, and Radiology, Nuclear Medicine, and Imaging for 2023. The journal operates within a well-defined scope that bridges innovative research and practical clinical applications, targeting professionals, researchers, and students keen on the intersection of nuclear medicine and imaging technologies. Although not an open-access journal, PET Clinics ensures accessibility through institutional subscriptions, making valuable insights available to the academic community. With an emphasis on enhancing patient care and treatment outcomes through cutting-edge imaging techniques, this journal serves as an essential resource for those seeking to expand their knowledge and expertise in the rapidly evolving field of PET.

BMC Medical Imaging is a premier open-access journal dedicated to advancing the field of radiology, nuclear medicine, and imaging technologies. Published by BMC in the United Kingdom, this journal serves as a vital resource for researchers, clinicians, and students, fostering a collaborative environment for sharing innovative findings and methodologies in medical imaging. With a commendable impact factor and an impressive Scopus ranking within the top 35% of its category, BMC Medical Imaging provides a platform for high-quality research to be disseminated widely and freely since its inception in 2001. The journal aims to cover a diverse array of topics, from advanced imaging techniques to their clinical applications, enhancing the understanding and effectiveness of diagnostic practices. By contributing to the body of knowledge and facilitating open access to research, BMC Medical Imaging plays a pivotal role in shaping the future of medical imaging and improving patient care.

Current Radiopharmaceuticals, published by Bentham Science Publishers Ltd, is an esteemed journal dedicated to advancing the field of radiopharmaceuticals. With an ISSN of 1874-4710 and an E-ISSN of 1874-4729, this journal has been a significant platform for researchers since its inception in 2009, and will continue to contribute to the literature until at least 2024. Current Radiopharmaceuticals is recognized for its impactful contributions, holding a record of Q3 in Pharmacology and Q2 in Radiology, Nuclear Medicine, and Imaging as of 2023, illustrating its vital role in these domains. The journal aims to provide a comprehensive overview of the latest techniques, applications, and innovations within the field of radiopharmaceutical science, catering to a diverse audience of researchers, professionals, and students. Despite its significant contributions, the journal remains committed to enriching the academic community with high-quality, peer-reviewed articles that can be accessed worldwide, reflecting a dedication to open dialogue and knowledge dissemination in radiopharmaceutical research.